NCT00454324View on ClinicalTrials.gov

Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

July 31, 2010

Study Completion Date

December 31, 2014

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Carboplatin

Carboplatin will be given at a dose of target area under the concentration versus time curve in mg/mL•min (AUC)=6, on Day 1 of a 21 Day Cycle

DRUG

Abraxane

"Abraxane will be given at a dose of 240mg/m2 on Day 1 of a 21 Day Cycle (Arm A)~Abraxane will be given at a dose of 80mg/m2 on Days 1, 8, and 15 of a 21 Day Cycle (Arm B)"

Trial Locations (1)

27599-7295

University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER